Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.08

-2.9%

Dec 26 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (1297)	7/3/2000 2:50:10 AM
From: Miljenko Zuanic	Read Replies (2) of 52153

Peter, <<Further, the FDA will be tougher (and hence slower) on a "new" new drug than on an "old" new drug.>> Why? NBIX candidate is Sonata sister (in theory) and (+)-Zopiclone is single enantiomer of the racemate, which never win FDA blessing. So, for FDA NBI34060 is “old” new (or me too) and (+)-Zopiclone is “new” new. Both candidates will need one year safety data and 6 months large pivotal data. SEPR have small lead (4-6 months), but clinical data will dictate market success. Somehow, I have gut-filing that NBI34060 is bit more than simple non-benzodiazepine hypnotic. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next